Cargando…

Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma

Gene expression-based scores used to predict risk in cancer frequently include genes coding for DNA replication, repair or recombination. Using two independent cohorts of 206 and 345 previously-untreated patients with Multiple Myeloma (MM), we identified 50 cell cycle-unrelated genes overexpressed i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kassambara, Alboukadel, Hose, Dirk, Moreaux, Jérôme, Rème, Thierry, Torrent, Jennifer, Rossi, Jean François, Goldschmidt, Hartmut, Klein, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409163/ https://www.ncbi.nlm.nih.gov/pubmed/22860071 http://dx.doi.org/10.1371/journal.pone.0042161

Ejemplares similares

Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells
por: Kassambara, Alboukadel, et al.
Publicado: (2013)

A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy
por: Kassambara, Alboukadel, et al.
Publicado: (2014)

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma
por: Hassen, Wafa, et al.
Publicado: (2014)

GenomicScape: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells
por: Kassambara, Alboukadel, et al.
Publicado: (2015)

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays
por: Mahtouk, Karène, et al.
Publicado: (2010)

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
por: Bruyer, Angelique, et al.
Publicado: (2018)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact
por: Devin, Julie, et al.
Publicado: (2019)

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
por: Viziteu, Elena, et al.
Publicado: (2016)

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value
por: Viziteu, Elena, et al.
Publicado: (2016)

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells
por: Lub, Susanne, et al.
Publicado: (2015)

Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020)

Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell
por: Kassambara, Alboukadel, et al.
Publicado: (2017)

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
por: Vikova, Veronika, et al.
Publicado: (2019)

Characterization of human FCRL4-positive B cells
por: Jourdan, Michel, et al.
Publicado: (2017)

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
por: Alaterre, Elina, et al.
Publicado: (2017)

An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy
por: Szablewski, Vanessa, et al.
Publicado: (2018)

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2021)

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression
por: Seckinger, Anja, et al.
Publicado: (2015)

RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators
por: Kassambara, Alboukadel, et al.
Publicado: (2021)

The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation
por: Chatonnet, Fabrice, et al.
Publicado: (2020)

A new method for class prediction based on signed-rank algorithms applied to Affymetrix(® )microarray experiments
por: Rème, Thierry, et al.
Publicado: (2008)

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018)

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
por: Rossi, J-F, et al.
Publicado: (2009)

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
por: Wagner, Verena, et al.
Publicado: (2014)

The Glycome of Normal and Malignant Plasma Cells
por: Moehler, Thomas M., et al.
Publicado: (2013)

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
por: Hose, Dirk, et al.
Publicado: (2019)

SULFs in human neoplasia: implication as progression and prognosis factors
por: Bret, Caroline, et al.
Publicado: (2011)

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
por: Emde-Rajaratnam, Martina, et al.
Publicado: (2023)

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells
por: Meißner, Tobias, et al.
Publicado: (2015)

SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma
por: Moreaux, Jerome
Publicado: (2014)

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
por: Viziteu, E, et al.
Publicado: (2017)

P843: METABOLOMIC CHARACTERIZATION OF HUMAN MULTIPLE MYELOMA CELL LINE TO STUDY TUMOR RESISTANCE TO DIFFERENT CLASSES OF THERAPEUTIC AGENTS
por: Steer, A., et al.
Publicado: (2022)

First Case of Plasma Cell Myeloma With Brown Tumor Features Unrelated to Hyperparathyroidism
por: Kim, Heyjin, et al.
Publicado: (2019)

The cell cycle and pluripotency
por: Hindley, Christopher, et al.
Publicado: (2013)

Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
por: Ovejero, Sara, et al.
Publicado: (2021)

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
por: Gourzones, Claire, et al.
Publicado: (2019)

Frequent Occurrence of Highly Expanded but Unrelated B-Cell Clones in Patients with Multiple Myeloma
por: Kriangkum, Jitra, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_17qca921ipst99mald63ku09ra